Effects of COVID-19 on the liver: The experience of a single center

Table 1 Characteristics of the studied patients

Variables	Group 1 (with elevated liver enzymes)		Group 2 (with normal liver enzymes)		P value
		Number of tested		Number of tested
n/%	603/88.2	603	81/11.8	81
Male, n/%	356/59.0	356	28/34.6	28	< 0.0001
Female, n/%	247/41.0	247	53/65.4	53
Age, yr ± SD	50.7 ± 9.5	603	51.9 ± 12.4	81	0.5075
Hospitalization, d ± SD	9.7 ± 5.9	603	8.7 ± 6.5	81	0.2039
ALT, U/L, range	149 ± 115, 40-728	603	22 ± 9, 7-39	81	< 0.0001
AST, U/L, range	90 ± 77, 3-818	552	22 ± 7, 11-39	70	< 0.0001
GGT, U/L, range	114 ± 125, 8-820	550	22 ± 8, 7-35	72	< 0.0001
ALP, U/L, range	101 ± 128, 29-1183	93	77 ± 25, 45-131	10	0.128
Bilirubin, μmol/L, range	9.1 ± 5.5, 3-67.1	460	7.6 ± 3.2, 3.2-18.5	61	0.0028
SPA, %, range	96.1 ± 19.5, 5-176	500	98.6 ± 21.9, 39-154	64	0.3868
INR, range	1.04 ± 0.18, 0.83-3.87	506	1.03 ± 0.11, 0.86-1.6	68	0.4728

ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; GGT: Gamma-glutamyl transferase; ALP: Alkaline phosphatase; INR: International normalized ratio; SPA: Stago prothrombin assay.